Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip...
-
Company advancing lead clinical-stage neoantigen cancer vaccine candidate and expanding pipeline into adoptive cell therapy Diantha Duvall to join as CFO, bringing broad life science financial...
-
CAMBRIDGE, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it will...
-
CAMBRIDGE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it has...
-
CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the dosing...
-
CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the hiring...
-
Event to be webcast live at 12 pm ET CAMBRIDGE, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer...
-
ATLAS™-identified “inhibitory” neoantigens promote tumor growth in mouse model ATLAS platform continues to differentiate versus in silico methods for true neoantigen identification CAMBRIDGE,...
-
Neoantigen vaccine program GEN-009 Phase 1/2a clinical trial enrolling patientsPresenting novel findings at upcoming SITC conference Conference call today at 9:00 am ET CAMBRIDGE, Mass., Nov. 01,...
-
CAMBRIDGE, Mass., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it will...